Search clinical trials for: EGFR L858R

Total 1597 results

City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
Fifth Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation (Neoafa)

Chemotherapy | Surgery | Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR TKI
University of Saskatchewan
Western Economic Diversification Canada

Recruiting

Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery

Lung Cancer

Canada
The First Affiliated Hospital of Guangzhou Medical...

Not yet recruiting

Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC (ANSWER)

Non-Small Cell Lung Cancer Stage IIIA

China
Bicara Therapeutics
Merck Sharp & Dohme LLC

Recruiting

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Head and Neck Neoplasms | Carcinoma, Squamous Cell | Colorectal Cancer | Squamous Cell Carcinoma of Head and Neck | Epithelial Ovarian Cancer | Head and Neck Squamous Cell Carcinoma | Pancreas Cancer | Squamous Cell Carcinoma of the Lung | Cutaneous Squamous Cell Carcinoma | Squamous Cell Carcinoma of... and other conditions

United States, Canada
Sunshine Lake Pharma Co., Ltd.

Recruiting

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Esophageal Cancer

China
Changchun Intellicrown Pharmaceutical Co. LTD
Covance

Recruiting

ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies

Advanced EGFR Positive Solid Tumor

United States, China
Memorial Sloan Kettering Cancer Center
AstraZeneca; Guardant Health, Inc.

Recruiting

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Metastatic Non-small Cell Lung Cancer

United States
Shanghai Chest Hospital

Recruiting

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

Non Small Cell Lung Cancer

China
Tian Xie
LinkDoc Technology (Beijing) Co. Ltd.

Recruiting

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study (SELECT-2)

Adenocarcinoma | Carcinoma | Non-Small-Cell Lung Cancer

China
Sun Yat-sen University
Tianjin Hengjia Biotechnology Development co., LTD

Recruiting

Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Fujian Cancer Hospital
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma (ARISE)

Pulmonary Adenosquamous Carcinoma

China
AstraZeneca

Recruiting

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NeoADAURA)

Non-Small Cell Lung Cancer

China, United States, Chile, Vietnam, Thailand, Brazil, Bulgaria, Canada, Germany, India, Japan, Korea, Republic of, Poland, Russian Federation, Singapore, Turkey, Austria, Israel, Spain, Taiwan, Mexico, France, Italy, Peru, Switzerland, United...
Guangdong Association of Clinical Trials

Not yet recruiting

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
Mark Vincent
AstraZeneca

Recruiting

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge (OCELOT)

Non-Small Cell Lung Cancer

Canada
Hunan Province Tumor Hospital

Recruiting

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (PIKACHU)

Non Small Cell Lung Cancer | ALK Gene Mutation | MET Gene Mutation | EGFR Gene Mutation | ROS1 Gene Mutation

China
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Altor BioScience; Miltenyi Biomedicine GmbH

Recruiting

CIML NK Cell in Head & Neck Cancer

Squamous Cell Carcinoma of the Head and Neck | Recurrent Head and Neck Squamous Cell Carcinoma

United States
University of Saskatchewan

Recruiting

Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)

Colorectal Cancer | Lung Cancer

Canada
University Hospital, Toulouse
Institut National de la Santé Et de la Recherche Médicale, France; National...

Recruiting

Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients (LUNG-RESIST)

Lung Cancer, Nonsmall Cell

France
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

Metastatic Lung Non-Small Cell Carcinoma | Anaplastic Astrocytoma, IDH-Wildtype | Glioblastoma, IDH-Wildtype | Metastatic Malignant Neoplasm in the Central Nervous System

United States
Shanghai Chest Hospital

Recruiting

Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

Non Small Cell Lung Cancer

China
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients

Lung Cancer Non-small Cell Stage IV
National Cancer Institute (NCI)

Recruiting

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
Pfizer

Recruiting

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

EGFR Mutation-positive Inoperable or Reccrent NSCLC

Japan
Konkuk University Medical Center
Foundation Medicine; Roche Diagnostics

Recruiting

Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study

Adenocarcinoma of Lung | EGFR Activating Mutation

Korea, Republic of
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China

Breast Cancer | Colorectal Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Other Solid Tumors | Pancreatic Ductal Carcinoma

China
Collin Blakely
Puma Biotechnology, Inc.

Recruiting

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Lung Cancer Metastatic | EGFR Gene Mutation

United States
National Cancer Center, Korea
Korean Cancer Study Group

Recruiting

EGFR-targeted Therapy for Gastric Cancer

Adenocarcinoma of the Stomach

Korea, Republic of
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy (SMART)

Non Small Cell Lung Cancer | Brain Metastases

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

Breast Cancer | Colorectal Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Other Solid Tumors | Pancreatic Ductal Carcinoma

United States
Centre Francois Baclesse
GFPC

Recruiting

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (GFPC 06-2018)

ALK Gene Rearrangement Positive | NSCLC Stage IV | NSCLC Stage IIIB | EGFR Gene Mutation | ROS1 Gene Mutation

France
Cullinan Therapeutics Inc.

Recruiting

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1)

Non Small Cell Lung Cancer | EGFR Exon 20 Mutation

United States, Taiwan, Spain, Korea, Republic of, Japan, Singapore, Italy, Netherlands, Hong Kong
Ludwig-Maximilians - University of Munich
Amgen; ClinAssess GmbH

Not yet recruiting

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

Treatment Related Cancer

Germany
Unity Health Toronto
University of Manitoba; University of British Columbia; University of Ottawa

Recruiting

Molecular Analysis of Diabetic Kidney Disease Biopsies

Diabetic Nephropathies | Kidney Disease, Chronic

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

Progressive Disease | Recurrent Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer... and other conditions

United States
Synthorx, Inc, a Sanofi company

Recruiting

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) (HAMMER)

Metastasis

United States, Australia, Singapore, Spain, Argentina, Chile
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

EGFR Positive Non-small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.

Non-squamous Non-small Cell Lung Cancer

China
King Abdullah Medical City

Recruiting

Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR (REPAN)

Metastatic Colorectal Cancer

Saudi Arabia
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Non-small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

EGFR-mutant Non-Small Cell Lung Cancer

China
Massachusetts General Hospital
Tesaro, Inc.

Recruiting

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

Lung Cancer

United States
Xin-Hua Xu

Recruiting

A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.

Nonsquamous Non-Small Cell Lung Cancer

China
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Guangdong Provincial People's Hospital

Not yet recruiting

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Advanced Non-small Cell Lung Cancer

China
AstraZeneca

Recruiting

Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation (PACIFIC-4)

Carcinoma, Non-Small-Cell Lung

United States, China, Korea, Republic of, Canada, Italy, Poland, Spain, Belgium, Netherlands, Japan, Germany, Brazil, Turkey, Russian Federation, United Kingdom, Greece, Israel, Australia, France, Puerto Rico
Xin-Hua Xu

Recruiting

A Study of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy

Nonsquamous Non-Small Cell Lung Cancer

China
Shanghai EpimAb Biotherapeutics Co., Ltd.
Covance

Recruiting

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Neoplasms | Neoplasm Metastasis | Non-Small-Cell Lung Cancer

United States, China
AstraZeneca
Hutchison MediPharma

Recruiting

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH)

Carcinoma

Denmark, Spain, United States, Taiwan, Vietnam, Canada, Korea, Republic of, Brazil, India, Japan, Italy, Puerto Rico, France, Chile
Rakuten Medical, Inc.

Recruiting

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Head and Neck Cancer

United States, Taiwan, Japan, India, Ukraine

Search clinical trials for: EGFR L858R

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations